NICE rejects ranibizumab in diabetic macular oedema

Following an appeal from the manufacturer, NICE has published a final technology appraisal on the use of ranibizumab in diabetic macular oedema.

Ranibizumab is a humanised recombinant monoclonal antibody fragment that targets human vascular endothelial growth factor A (VEGF-A)
Ranibizumab is a humanised recombinant monoclonal antibody fragment that targets human vascular endothelial growth factor A (VEGF-A)
The National Institute for Health and Care Excellence (NICE) has made the decision that ranibizumab (Lucentis) should not be made available on the NHS for the treatment of diabetic macular oedema (DMO).

NICE rejected the appeal by Novartis on its previous decision to not recommend the drug, deciding that it was not cost-effective.

DMO can lead to sight loss as a result of leaking plasma from the small retinal blood vessels in the eye. On the NHS, the available treatment is laser photocoagulation.

Ranibizumab is recommended by NICE for the treatment of wet age-related macular degeneration.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases